Previous 10 | Next 10 |
2024-06-17 13:29:18 ET Summary Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. ...
2024-06-16 11:15:16 ET Summary Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficie...
2024-06-14 15:00:00 ET More on the markets SPY Is Sub-Optimal For Long-Term Diversified Investors S&P 500 Peaks And VIX Valleys As Market Signals Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) Citi says ETFs will engulf U.S. as...
2024-06-13 15:15:01 ET Citigroup analyst issues BUY recommendation for SRPT on June 13, 2024 01:18PM ET. The previous analyst recommendation was Buy. SRPT was trading at $123.865 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-06-13 11:00:06 ET Brian Skorney from Robert W. Baird issued a price target of $170.00 for SRPT on 2024-06-13 10:14:00. The adjusted price target was set to $170.00. At the time of the announcement, SRPT was trading at $124. The overall price target consensus is at $...
2024-06-13 09:00:00 ET U.S. stock index futures on Thursday were mixed . Wall Street's benchmark and tech-heavy gauges were on track to extend their gains from the previous session, but its blue-chip average looked set to add onto losses. Here are some stocks to watch on Thursday: ...
2024-06-13 07:15:05 ET Barclays analyst issues OVERWEIGHT recommendation for SRPT on June 13, 2024 05:41AM ET. The previous analyst recommendation was Overweight. SRPT was trading at $119.98 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-13 07:00:26 ET More on Pfizer, Roche, etc. Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates ...
2024-06-13 07:00:07 ET Gena Wang from Barclays issued a price target of $185.00 for SRPT on 2024-06-13 05:41:00. The adjusted price target was set to $185.00. At the time of the announcement, SRPT was trading at $119.98. The overall price target consensus is at $152.45 w...
2024-06-07 09:00:09 ET Kostas Biliouris from BMO Capital issued a price target of $170.00 for SRPT on 2024-06-07 07:23:00. The adjusted price target was set to $170.00. At the time of the announcement, SRPT was trading at $117.44. The overall price target consensus is at...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 08:00:00 ET On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy (DMD), Elevidys, from an accelerated approval to a full appro...